GlassScriptPhysician profile
Matthew Mates
NPI 1033188933
$3,977.68
in general payments reported to CMS, 2019-2025
33 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $878 · 2022: $962 · 2023: $862 · 2024: $794 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $593.09 | 2021-2025 | Xtandi, Myrbetriq, Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $338.71 | 2021-2025 | |
| Blue Earth Diagnostics | $337.63 | 2021-2025 | Posluma |
| Convatec INC. | $267.03 | 2021-2025 | |
| Antares Pharma, INC. | $250.82 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Progenics Pharmaceuticals, INC. | $224.40 | 2021-2024 | Pylarify |
| Tolmar Pharmaceuticals, INC. | $160.77 | 2021-2022 | |
| Janssen Biotech, INC. | $155.03 | 2021-2025 | Erleada, Akeega |
| Urovant Sciences INC | $146.89 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $146.55 | 2022-2024 | Provenge |
| Teleflex LLC | $141.93 | 2021 | |
| Tolmar, INC. | $133.31 | 2023-2025 | Eligard, Jatenzo, Rubraca |
| Genzyme Corporation | $132.87 | 2023 | |
| Novartis Pharmaceuticals Corporation | $129.79 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $105.31 | 2023-2025 | Gemtesa, Orgovyx |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $96.95 | 2021-2022 | |
| Verity Pharmaceuticals INC. | $78.40 | 2022-2024 | Trelstar |
| Dentsply Ih Ab | $72.13 | 2022-2024 | Lofric |
| Abbvie INC. | $69.14 | 2021-2022 | |
| Boston Scientific Corporation | $61.08 | 2024-2025 | Ams 700 |
| Myovant Sciences INC. | $43.46 | 2021-2022 | |
| Urogen Pharma, INC. | $39.58 | 2021-2023 | Jelmyto |
| Immunitybio, INC. | $36.67 | 2025 | |
| Coloplast Corp | $34.65 | 2021-2022 | |
| Calyxo, INC. | $29.47 | 2024-2025 | Cvac Aspiration System |
| Clarus Therapeutics INC. | $26.02 | 2021 | |
| Abc Home Medical Supply, INC. | $25.72 | 2025 | |
| Amgen INC. | $20.43 | 2021 | |
| Pharmaand Gmbh | $18.08 | 2025 | Rubraca |
| Laborie Medical Technologies Corp. | $17.28 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $15.77 | 2024 | Lynparza |
| Acerus Pharmaceuticals Corporation | $15.56 | 2021 | |
| Photocure INC | $13.16 | 2023 | Cysview |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.